Inspirion Delivery Technologies LLC
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Inspirion Delivery Technologies LLC
Opioid Sponsors Enter 2019 At A Crossroads
Recent regulatory trends at US FDA offer no clear path to success for sponsors developing opioids. As 2018 concludes with only one approval and at least five rejections, firms will need new strategies if they hope to bring the
PMRS Continues Campaign Against Other Abuse Deterrent Opioid Products
Latest citizen petition seeks to halt US FDA approval of Mallinckrodt's immediate release oxycodone abuse deterrent formulation; user fee action date is Nov. 16.
Mallinckrodt's Abuse-Deterrent Oxycodone IR May Face Hurdle At US FDA Panel
FDA finds no benefit in deterring intranasal abuse; final data not yet submitted to determine IV abuse deterrence.
PTI's Remoxy: US FDA Panel To Weigh Intranasal Abuse Deterrence Against Oral Abuse Potential
Agency reviewers see lower potential for intranasal abuse with Pain Therapeutics' extended-release opioid compared to immediate-release oxycodone, but an increased abuse potential when Remoxy is chewed compared to swallowing the drug intact.
Company Information
- Industry
-
Biotechnology
- Liposomes
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice